109.62MMarket Cap-948P/E (TTM)
4.6100High4.1500Low512.57KVolume4.3800Open4.3500Pre Close2.20MTurnover2.15%Turnover RatioLossP/E (Static)26.10MShares14.748052wk High1.49P/B100.30MFloat Cap3.850052wk Low--Dividend TTM23.88MShs Float2352.0000Historical High--Div YieldTTM10.58%Amplitude3.8500Historical Low4.2830Avg Price1Lot Size
Inovio Pharmaceuticals Stock Forum
New Retrospective Data Shows Half of Rrp Patients Treated With Ino-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
Inovio Announces New Data at Scientific Conferences for Lead Candidate, Ino-3107, as a Potential Treatment for Rrp
On Friday, the fear of human-to-human spread grew ever so slightly: The CDC confirmed that four health-care workers in Missouri had fallen sick after caring for a patient who was infected with bird flu.
https://www.msn.com/en-us/health/other/bird-flu-pandemic-fears-skyrocket-as-us-identifies-first-cases-of-possible-human-to-human-transmission/ar-AA1rwhf5?ocid=BingNewsSerp
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet